Medpace (MEDP)

Yatırım Radar

Catch Opportunities on Your Radar

Agenda Radar Daily Digest My Watchlist

Markets Assets Consensus Signals Economic Calendar

Analysts Compare Analysts

Sectors Themes Ideas Screener

Smart Score Compare Asset Relations

Changes Seasonal Analysis Category Rotation

Video Impact Forgotten Picks Coverage Gaps My Analytics Community Pulse

Blog Premium

📱Mobile App

Your radar, pocket-sized

Real-time alerts, Premium checkout, and the full experience on mobile.

App Store Google Play

Not investment advice under CMB regulations. Every analysis links to its source and is reviewed by editors. Methodology ·

About Us Methodology Masthead FAQ Blog Privacy Policy Terms of Service Contact

Agenda Radar Daily Digest My Watchlist Markets Assets Consensus Signals Economic Calendar Analysts Compare Analysts Sectors Themes Ideas Screener Smart Score Compare Asset Relations Changes Seasonal Analysis Category Rotation Video Impact Forgotten Picks Coverage Gaps My Analytics Community Pulse Blog Premium

Yatırım Radar

Catch Opportunities on Your Radar

Medpace (MEDP) | Asset Consensus | Yatirim Radar | Yatırım Radar

AssetsMedpace (MEDP)Analysis

MED

Asset · Weak Signal

Medpace (MEDP)

Price unavailable1 calls · 0+ analysts · last 90 days

Radar Score

Weak Signal

Radar profile

5-factor impact analysis

Coverage, strength, recency, conviction and momentum.

Factor notes

Detailed grading

No analyses found yet.

Consensus history

How recommendation distribution changed over time

Strong BuyBuyHoldSellStrong Sell

Not enough data to chart consensus history.

Recommendation distribution

1 total calls

Strong Buy0 · %0

Buy0 · %0

Hold0 · %0

Sell0 · %0

Strong Sell0 · %0

Recommendation timeline

Chronological view of analyst calls on this asset

Newest calls at the top.

Dec 27, 20253 months ago
BuybyDavidYahoo Finance
The speaker discusses the company's business model facilitating biotech trials and its growth story independent of economic cycles.

Recent analyses

Recent calls on Medpace (MEDP)

International Stocks

Buy

The speaker discusses the company's business model facilitating biotech trials and its growth story independent of economic cycles.

David

Yahoo Finance

116d

Price Chart + Analyst Markers

No price data available for this asset.

Price Chart + Analyst Markers

No price data available for this asset.